DDInter1577 DDInter1016
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name Orgovyx, for the treatment of advanced prostate cancer.[L27991,L27996] This branded product was later approved by the European Commission on April 29, 2022. Relugolix has also been studied in the symptomatic treatment of endometriosis. Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist approved for the treatment of prostate cancer - similar therapies such as [degarelix] require subcutaneous administration - and therefore provides a less burdensome therapeutic option for patients who might otherwise require clinic visits for administration
Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose]. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in patients with cirrhosis.[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.
Relugolix {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enzalutamide
Relugolix {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brigatinib
Relugolix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Relugolix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Relugolix {u} may lead to a major life threatening interaction when taken with {v} Ticagrelor
Relugolix {u} may lead to a major life threatening interaction when taken with {v} Elagolix
Relugolix may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Relugolix may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Relugolix may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Relugolix may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Relugolix may lead to a major life threatening interaction when taken with Ticagrelor
Relugolix may lead to a major life threatening interaction when taken with Elagolix